{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-012018","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.155361+00:00","generated_at":"2026-05-27T04:06:11.710037+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd reports preliminary Q4 revenue of $13.8M; positive Phase 1/2 data for VYD2311","bullets":["Preliminary Q4 PEMGARDA net revenue $13.8M, 48% growth over Q3; total operating costs $32M, 55% reduction.","Cash and equivalents $69.3M; accounts receivable $10.9M; targets near-term profitability by end of 1H 2025.","Positive Phase 1/2 data for VYD2311: safety mild/moderate, serum concentrations high at Day 65, half-life not reached.","VYD2311 shows average 17-fold greater in vitro neutralization potency vs pemivibart across contemporary SARS-CoV-2 variants.","Potential clinical profile: 70-90% protection from symptomatic COVID-19 with once- or twice-annual dosing, also as treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-012018","json":"https://secwatch.observer/filing/0000950170-25-012018.json","markdown":"https://secwatch.observer/filing/0000950170-25-012018.md","text":"https://secwatch.observer/filing/0000950170-25-012018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/0000950170-25-012018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/ivvd-20250203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:06:11.710037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}